Are three weeks hypofractionated radiation therapy (HFRT) comparable to six weeks for newly diagnosed glioblastoma patients? Results of a phase II study
Matteo Simonelli
Oncotarget, 2017
View PDFchevron_right
Short Course versus Standard Course of Radiotherapy in Glioblastoma Multiforme
Amr Sakr
Journal of Nuclear Medicine & Radiation Therapy, 2018
View PDFchevron_right
RT-14 * Time to Radiation Therapy in Glioblastoma Multiforme: Is Sooner Better?
Heather Kistka
Neuro-oncology, 2014
View PDFchevron_right
A clinical review of treatment outcomes in glioblastoma multiforme--thevalidation in a non-trial population of the results of a randomised PhaseIII clinical trial: has a more radical approach improved survival?
Mary Dunne
British Journal of Radiology, 2012
View PDFchevron_right
Clinical characterization of glioblastoma patients living longer than 2 years: A retrospective analysis of two Italian institutions
Cynthia Aristei
Asia-Pacific Journal of Clinical Oncology, 2020
View PDFchevron_right
Radiation Therapy Dose Escalation for Glioblastoma Multiforme in the Era of Temozolomide
Michael Chicoine
International Journal of Radiation Oncology*Biology*Physics, 2014
View PDFchevron_right
Survival impact of prolonged postoperative radiation therapy for patients with glioblastoma treated with combined-modality therapy
Shiao Woo
Neuro-Oncology Practice, 2018
View PDFchevron_right
Impact of timing of radiotherapy in patients with newly diagnosed glioblastoma
Stephen Tatter
Clinical Neurology and Neurosurgery, 2016
View PDFchevron_right
Postoperative Radiotherapy of Glioblastoma Multiforme
Michael Pinkawa
Strahlentherapie und Onkologie, 2007
View PDFchevron_right
The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme
Kurt Jaeckle
Neuro-Oncology, 2006
View PDFchevron_right
Survival effect of first- and second-line treatments for patients with primary glioblastoma: a cohort study from a prospective registry, 1997-2010
maria grazia bruzzone
Neuro-Oncology, 2014
View PDFchevron_right
Chemoirradiation for Glioblastoma Multiforme: The National Cancer Institute Experience
Uma Shankavaram
PLoS ONE, 2013
View PDFchevron_right
Optimal timing of chemoradiotherapy after surgical resection of glioblastoma: Stratification by validated prognostic classification
Soma Sengupta
Cancer, 2020
View PDFchevron_right
Safety of second-line chemotherapy with non-conventional fotemustine schedule in recurrent high grade gliomas: a single institution experience
Antonio Silvani
Journal of Neuro-Oncology, 2013
View PDFchevron_right
Comparison of radiation regimens in the treatment of Glioblastoma multiforme: results from a single institution
Luis Souhami
Radiation oncology (London, England), 2015
View PDFchevron_right
A phase II study of extended low-dose temozolomide in recurrent malignant gliomas
Raja Mushtaq Ahmad Khan
Neuro-Oncology, 2002
View PDFchevron_right
Short-term radiotherapy followed by adjuvant chemotherapy in poor-prognosis patients with glioblastoma
Giuseppe Minniti
Tumori, 2010
View PDFchevron_right
Hypo-fractionated accelerated radiotherapy with concurrent and maintenance temozolomide in newly diagnosed glioblastoma: updated results from phase II HART-GBM trial
Dayanand Sharma
Journal of Neuro-oncology, 2023
View PDFchevron_right
Innovative Hypofractionated Stereotactic Regimen Achieves Excellent Local Control With No Radiation Necrosis: Promising Results in the Management of Patients With Small Recurrent Inoperable GBM
Jenghwa Chang
International Journal of Radiation Oncology*Biology*Physics, 2015
View PDFchevron_right
Survival of High Grade Glioma Patients Treated by Three Radiation Schedules with Chemotherapy: A Retrospective Comparative Study
Hamza Abubakar
Research in Oncology, 2017
View PDFchevron_right
Extended Daily Schedule of Temozolomide in Recurrent Glioblastoma: Single-Institution Report on a Series of 43 Patients
vincenza maiola
Journal of Cancer Therapy, 2014
View PDFchevron_right
Impact of beta-blocker use on outcomes for glioblastoma multiforme (GBM) patients
Peter Gan
Clinical Oncology, 2018
View PDFchevron_right
Treatment Patterns and Outcomes Among Elderly Glioblastoma Patients in Riyadh, Saudi Arabia
Wafaa Alshakweer
OncoTargets and Therapy
View PDFchevron_right
Radiotherapy with concurrent or sequential temozolomide in elderly patients with glioblastoma multiforme
Chandrababu Rejeeth, Maher Sughayer, Ahmed Salem
Journal of Medical Imaging and Radiation Oncology, 2012
View PDFchevron_right
Impact of waiting time after surgery and overall time of postoperative radiochemotherapy on treatment outcome in glioblastoma multiforme
Steffen Löck
Radiation Oncology, 2015
View PDFchevron_right
Limited Margins Using Modern Radiotherapy Techniques Does Not Increase Marginal Failure Rate of Glioblastoma
Stephen Tatter
American Journal of Clinical Oncology, 2014
View PDFchevron_right
The content and efficacy of conventional methods of follow-up in neuro-oncology: The need for new strategies
Michael Brada
Clinical Oncology, 1997
View PDFchevron_right
Survival in a consecutive series of 467 glioblastoma patients: Association with prognostic factors and treatment at recurrence at two independent institutions
Mohummad Aminur Rahman
PLOS ONE, 2023
View PDFchevron_right
Frequently asked questions in the medical management of high-grade glioma: a short guide with practical answers
Andreas Hottinger
Annals of Oncology, 2008
View PDFchevron_right
Survival analysis of HDR brachytherapy versus reoperation versus temozolomide alone: a retrospective cohort analysis of recurrent glioblastoma multiforme
Eleftherios Archavlis
View PDFchevron_right
A retrospective pooled analysis of response patterns and risk factors in recurrent malignant glioma patients receiving a nitrosourea-based chemotherapy
Maria Grazia Fabrini
Journal of Translational Medicine, 2012
View PDFchevron_right